It's not what you do but that kind of job you do that makes the difference.” ― Ben Carson
Biotech will try to end the holiday shortened trading week today on a high note. The sector is flat to begin the trading day.
Here are four small healthcare stocks getting some positive attention from analysts this Friday.
We are reiterating our Overweight rating and increasing our 12-month price target to $8, from $5. Our price target increase is driven by upwards earnings revisions for Belbuca. We believe Belbuca peak sales could exceed $300MM, above the $200MM+ management has previously guided to. Belbuca is a product which has found itself at the right place at the right time. That said, we believe BDSI is an execution story, and given the strong execution of the BDSI team to date, we are confident the company can continue to execute and fully maximize the value of Belbuca. As BDSI continues to execute we would expect further upwards earnings revisions to drive the stock higher.”"
Craig-Hallum maintains its buy rating and raises its price target on Exact Sciences (EXAS) this morning after the company posted Q4 results. Hallum's analyst 'believes the company carries strong momentum on Cologuard into 2019 driven by the Pfizer (PFE) co-promotion agreement, expanded sales force, greater market access and expanded TV campaign. While the estimated loss widens on higher opex," the analyst "sees the investments driving continued strong top line growth and adds that a Cologuard label expansion into the 45-49 age group, a 20M/$4B increase in TAM, is seen as a 1H20 development."
Given the stock has reached $85 a share, not exactly an aggressive upward price target revision.
For those that want to use simple option strategies to enhance returns and mitigate risk (which I highly recommend in the volatile biotech space), you can pick up a free report entitled '10 Simple Rules To Trade Options Like A Pro' from our friends at Investors Alley. It is now available free via download HERE
Lake Street likes BioTelemetry (BEAT) after its strong fourth quarter results and projects it will have a good 2019. Their reiterated their Buy rating. Lake Street's analyst 'believes remote patient monitoring is in its infancy and that BioTelemetry is the leader in this "exciting space"'. The market is of a different opinion as BEAT is trading down some 8% in early going today after results posted after the bell Thursday.
We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35.”
And those are four small cap concerns getting positive analyst commentary this Friday morning.
Money can't buy happiness but it can buy a huge yacht that sails right next to it.” ― David Lee Roth
Thank You & Happy Hunting,